AR086576A1 - Composiciones de cb-183,315 y metodos relacionados - Google Patents

Composiciones de cb-183,315 y metodos relacionados

Info

Publication number
AR086576A1
AR086576A1 ARP120101868A ARP120101868A AR086576A1 AR 086576 A1 AR086576 A1 AR 086576A1 AR P120101868 A ARP120101868 A AR P120101868A AR P120101868 A ARP120101868 A AR P120101868A AR 086576 A1 AR086576 A1 AR 086576A1
Authority
AR
Argentina
Prior art keywords
compositions
related methods
solid
aqueous solution
trehalose
Prior art date
Application number
ARP120101868A
Other languages
English (en)
Spanish (es)
Inventor
Sandra Oconnor
Sophie Sun
Gaauri Naik
Original Assignee
Cubist Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cubist Pharm Inc filed Critical Cubist Pharm Inc
Publication of AR086576A1 publication Critical patent/AR086576A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP120101868A 2011-05-26 2012-05-28 Composiciones de cb-183,315 y metodos relacionados AR086576A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161490584P 2011-05-26 2011-05-26

Publications (1)

Publication Number Publication Date
AR086576A1 true AR086576A1 (es) 2014-01-08

Family

ID=46208839

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120101868A AR086576A1 (es) 2011-05-26 2012-05-28 Composiciones de cb-183,315 y metodos relacionados

Country Status (12)

Country Link
US (2) US20130109633A1 (enExample)
EP (1) EP2714012A1 (enExample)
JP (1) JP2014515371A (enExample)
KR (1) KR20140037877A (enExample)
CN (1) CN103687589A (enExample)
AR (1) AR086576A1 (enExample)
BR (1) BR112013030369A2 (enExample)
CA (1) CA2837174A1 (enExample)
MX (1) MX2013013760A (enExample)
RU (1) RU2013157188A (enExample)
TW (1) TW201300124A (enExample)
WO (1) WO2012162567A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109476704B (zh) * 2016-04-08 2022-08-16 港大科桥有限公司 抗菌环脂肽
US11667674B2 (en) 2016-04-08 2023-06-06 Versitech Limited Antibacterial cyclic lipopeptides
US10647746B2 (en) 2016-04-08 2020-05-12 Versitech Limited Antibacterial cyclic lipopeptides

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001044271A2 (en) * 1999-12-15 2001-06-21 Cubist Pharmaceuticals, Inc. Daptomycin analogs and their use as antibacterial agents
CA2413251C (en) * 2000-06-21 2012-06-12 Cubist Pharmaceuticals, Inc. Compositions and methods to improve the oral absorption of antimicrobial agents
AU2002246688A1 (en) * 2000-12-18 2002-07-30 Altus Biologics Inc. Methods for preparing purified daptomycin
EP1814588A2 (en) * 2004-11-12 2007-08-08 Cubist Pharmaceuticals, Inc. Antiinfective lipopeptides
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
RU2512396C2 (ru) * 2008-12-22 2014-04-10 Кьюбист Фармасьютикалз, Инк. Новые противобактериальные средства для лечения грамположительных инфекций
JP5491119B2 (ja) * 2009-10-02 2014-05-14 日東電工株式会社 薬物含有微粒子を含む医薬組成物およびその製造方法
CN102060914B (zh) * 2009-11-13 2014-09-17 华东理工大学 海洋芽孢杆菌b-9987产脂肽类化合物及其制备和应用
BR112012012406B1 (pt) * 2009-11-23 2021-11-16 Cubist Pharmaceuticals Llc Composições farmacêuticas sólidas de daptomicina, seu produto farmacêutico e seus métodos de fabricação
US20110124551A1 (en) * 2009-11-23 2011-05-26 Eagle Pharmaceuticals, Inc. Formulations of daptomycin

Also Published As

Publication number Publication date
RU2013157188A (ru) 2015-07-10
TW201300124A (zh) 2013-01-01
MX2013013760A (es) 2014-01-08
BR112013030369A2 (pt) 2016-12-13
KR20140037877A (ko) 2014-03-27
US20140135273A1 (en) 2014-05-15
US20130109633A1 (en) 2013-05-02
CA2837174A1 (en) 2012-11-29
CN103687589A (zh) 2014-03-26
EP2714012A1 (en) 2014-04-09
WO2012162567A1 (en) 2012-11-29
JP2014515371A (ja) 2014-06-30

Similar Documents

Publication Publication Date Title
BR112015013822A2 (pt) método de vaso único para a síntese de cu-ssz-13, o composto obtido através do método e utilização do mesmo
CL2019002190A1 (es) Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984)
WO2017070616A3 (en) Sexually transmitted disease vaccines
EA201590890A1 (ru) Производные 5-фтор-n-(пиридин-2-ил)пиридин-2-амина, содержащие сульфоксиминовую группу
WO2017070626A3 (en) Respiratory virus vaccines
CL2011002460A1 (es) Torta liofilizada que comprende un inhibidor de proteasoma derivado del acido protonico, una ciclodextrina, y al menos un agente espesante y/o un surfactante; metodo para su fabricacion; y su uso en el tratamiento de mieloma multiple.
PE20181400A1 (es) Formulacion farmaceutica acuosa del anticuerpo anti-pd-l1 avelumab
MX391216B (es) Composicion farmaceutica que comprende un vector adenoviral.
BR112015015031A2 (pt) processo de glicoconjugação
AR095496A1 (es) Formulaciones de anticuerpos anti-receptor de prolactina
EA202090675A3 (ru) Стабилизированные растворимые f-полипептиды rsv до слияния
BR112015030326A2 (pt) Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
GB2499479A (en) Stabilisation of viral particles
CL2014003012A1 (es) Formulación en capsulas que comprende al menos un compuesto de formula (i), solubilizado; metodo de administracion de la formulacion; uso para tratar una infeccion por el virus de la hepatitis c.
BR112017017747A2 (pt) processo de preparação de um extrato de matriz vegetal com um composto anfifílico não iônico como adjuvante de extração em meio aquoso
HK1217295A1 (zh) 4'-疊氮基,3'-脫氧基-3'-氟取代的核苷衍生物
EA201891576A1 (ru) Функционализированные пентановые кислоты для применения при инфекциях, вызванных вирусом гриппа
EA201990163A1 (ru) Консервация микроорганизмов
UY35848A (es) Tienopirimidinas
BR112015028824A2 (pt) composição de tensoativo concentrada
BR112018014401A2 (pt) composições pulverizadas sólidas com substâncias ativas de superfície em carreadores solúveis em água sólidos, seu processo para a produção e uso das mesmas?
BR112015013071A2 (pt) solução de trombina e seus métodos de uso
CO2017000010A2 (es) Proceso para la preparacion de ácidos 3-hidroxipicolínicos
EA201991023A1 (ru) Фармацевтическая композиция для парентерального введения, содержащая карглумовую кислоту
WO2013117771A3 (en) Cosmetic treatment method, and composition comprising a glyoxylic acid derivative

Legal Events

Date Code Title Description
FB Suspension of granting procedure